Scholar Rock Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 Spinal Muscular Atrophy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. META
5. SPY
6. ACN
7. NVDA
8. BLZE
9. IBM
10. PRIM

Go back to Scholar Rock Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 Spinal Muscular Atrophy

Scholar Rock (SRRK) PT Raised to $52 at BMO Capital

October 27, 2020 3:39 PM EDT

BMO Capital analyst Do Kim raised the price target on Scholar Rock (NASDAQ: SRRK) to $52.00 (from $33.00) while maintaining an Outperform rating.

The analyst commented, "We raise our SRK-015 estimates and target price to $52 from $33, as our probability of success increase to 50% from 33%, following... More